AMELIORATIVE EFFECTS OF SELECTIVE PDE-10 INHIBITORS AGAINST KETAMINE-MEDIATED SCHIZOPHRENIC OUTCOMES IN MICE
Asian Journal of Pharmaceutical and Clinical Research January 7, 2026 Ruchika Srivastava, Prabhat Singh, Ajeet
A phosphodiesterase-10 inhibitor, papaverine, protected mice from schizophrenia-like behavioral and brain changes caused by ketamine. Mice given ketamine for 10 days showed increased immobility, altered movement and anxiety-like behavior, reduced social interaction, cognitive impairment, and catalepsy, along with higher oxidative stress and altered acetylcholinesterase activity and brain histology. Both papaverine and the standard antipsychotic clozapine significantly reversed these behavioral, biochemical, and histological abnormalities. The findings suggest papaverine may have neuroprotective potential against schizophrenia-related deficits.